目的探讨窄带成像放大内镜(narrow band imaging magnification endoscopy,NBI-ME)分级系统在慢性萎缩性胃炎(chronic atrophic gastritis,CAG)实时诊断及危险分层中的价值。方法收集40岁以上接受NBI-ME检查患者的内镜和病理资料,评估NB...目的探讨窄带成像放大内镜(narrow band imaging magnification endoscopy,NBI-ME)分级系统在慢性萎缩性胃炎(chronic atrophic gastritis,CAG)实时诊断及危险分层中的价值。方法收集40岁以上接受NBI-ME检查患者的内镜和病理资料,评估NBI-ME分级系统和组织病理学金标准—OLGA/OLGIM(operative link for gastritis assessment/operative link for gastric intestinal metaplasia assessment)分期系统的相关性及一致性。结果共纳入63例患者,男41例,女22例,胃窦和胃体部的NBI-ME评分和组织学评分的一致性均为73.0%,总体一致性显著(Kappa=0.695,P<0.05;加权Kappa=0.907,P<0.05),其中胃窦的一致性良好(Kappa=0.604,P<0.05),胃体的一致性中等(Kappa=0.487,P<0.05);Cochran-Mantel-Haenszel分析表明,高危NBI-ME分级(Ⅱ~Ⅳ级)的患者诊断为高危OLGA/OLGIM分期的可能性更高(P<0.0001),NBI-ME分级诊断高危CAG/GIM的敏感性为81.8%(95%CI:59.7%~94.8%),特异性为95.1%(95%CI:83.5%~99.4%)。结论NBI-ME评分与组织病理学评分具有较高一致性,它是一种简便、经济并实时诊断CAG及识别胃癌高危人群的检查及随访方式。展开更多
In 2023, major global powers competed in the South Pacific, thus reigniting regional tensions. In response to novel circumstances and new changes, regional powers, notably Australia and New Zealand, have adjusted thei...In 2023, major global powers competed in the South Pacific, thus reigniting regional tensions. In response to novel circumstances and new changes, regional powers, notably Australia and New Zealand, have adjusted their security strategies. Despite headwinds, China has steadily advanced its relations with Oceanian countries.展开更多
目的:采用超高效液相色谱-串联质谱(UPLC-MS/MS)法建立同时测定藤黄药材中藤黄酸、转位藤黄酸、藤黄酸B、异藤黄酸、新藤黄酸5种成分的含量。方法:藤黄药材经75%乙醇水超声提取,以ZORBAX Eclipse Plus C18为色谱柱、0.1%甲酸水-乙腈(30...目的:采用超高效液相色谱-串联质谱(UPLC-MS/MS)法建立同时测定藤黄药材中藤黄酸、转位藤黄酸、藤黄酸B、异藤黄酸、新藤黄酸5种成分的含量。方法:藤黄药材经75%乙醇水超声提取,以ZORBAX Eclipse Plus C18为色谱柱、0.1%甲酸水-乙腈(30∶70,V/V)为流动相,流速为0.4 m L/min,柱温为35℃;质谱采用电喷雾离子(ESI)源、正离子扫描的多反应监测(MRM)模式进行定量分析。结果:藤黄酸、转位藤黄酸、藤黄酸B、异藤黄酸、新藤黄酸分别在51.00~1020、3.749~74.98、8.675~173.5、60.00~1200、47.95~959 ng/mL(r均大于0.9990)的浓度范围内呈现良好的线性关系。5种成分的平均加样回收率分别为97.2%、98.1%、97.9%、97.0%、99.3%,RSD分别为2.1%、2.1%、2.3%、1.9%、2.1%。藤黄药材中上述5种成分含量分别为22.98%~23.63%、1.28%~1.35%、2.78%~2.89%、26.13%~26.54%、22.29%~22.40%。结论:该方法操作简便、准确、可靠,可用于藤黄药材的多指标成分定量测定。展开更多
文摘目的探讨窄带成像放大内镜(narrow band imaging magnification endoscopy,NBI-ME)分级系统在慢性萎缩性胃炎(chronic atrophic gastritis,CAG)实时诊断及危险分层中的价值。方法收集40岁以上接受NBI-ME检查患者的内镜和病理资料,评估NBI-ME分级系统和组织病理学金标准—OLGA/OLGIM(operative link for gastritis assessment/operative link for gastric intestinal metaplasia assessment)分期系统的相关性及一致性。结果共纳入63例患者,男41例,女22例,胃窦和胃体部的NBI-ME评分和组织学评分的一致性均为73.0%,总体一致性显著(Kappa=0.695,P<0.05;加权Kappa=0.907,P<0.05),其中胃窦的一致性良好(Kappa=0.604,P<0.05),胃体的一致性中等(Kappa=0.487,P<0.05);Cochran-Mantel-Haenszel分析表明,高危NBI-ME分级(Ⅱ~Ⅳ级)的患者诊断为高危OLGA/OLGIM分期的可能性更高(P<0.0001),NBI-ME分级诊断高危CAG/GIM的敏感性为81.8%(95%CI:59.7%~94.8%),特异性为95.1%(95%CI:83.5%~99.4%)。结论NBI-ME评分与组织病理学评分具有较高一致性,它是一种简便、经济并实时诊断CAG及识别胃癌高危人群的检查及随访方式。
文摘In 2023, major global powers competed in the South Pacific, thus reigniting regional tensions. In response to novel circumstances and new changes, regional powers, notably Australia and New Zealand, have adjusted their security strategies. Despite headwinds, China has steadily advanced its relations with Oceanian countries.
文摘目的:采用超高效液相色谱-串联质谱(UPLC-MS/MS)法建立同时测定藤黄药材中藤黄酸、转位藤黄酸、藤黄酸B、异藤黄酸、新藤黄酸5种成分的含量。方法:藤黄药材经75%乙醇水超声提取,以ZORBAX Eclipse Plus C18为色谱柱、0.1%甲酸水-乙腈(30∶70,V/V)为流动相,流速为0.4 m L/min,柱温为35℃;质谱采用电喷雾离子(ESI)源、正离子扫描的多反应监测(MRM)模式进行定量分析。结果:藤黄酸、转位藤黄酸、藤黄酸B、异藤黄酸、新藤黄酸分别在51.00~1020、3.749~74.98、8.675~173.5、60.00~1200、47.95~959 ng/mL(r均大于0.9990)的浓度范围内呈现良好的线性关系。5种成分的平均加样回收率分别为97.2%、98.1%、97.9%、97.0%、99.3%,RSD分别为2.1%、2.1%、2.3%、1.9%、2.1%。藤黄药材中上述5种成分含量分别为22.98%~23.63%、1.28%~1.35%、2.78%~2.89%、26.13%~26.54%、22.29%~22.40%。结论:该方法操作简便、准确、可靠,可用于藤黄药材的多指标成分定量测定。
